A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization

J Neurochem. 2003 Dec;87(6):1558-67. doi: 10.1111/j.1471-4159.2003.02265.x.

Abstract

The identification of genetic mutations responsible for rare familial forms of Parkinson's disease (PD) have provided tremendous insight into the molecular pathogenesis of this disorder. Mutations in the DJ-1 gene cause autosomal recessive early onset PD in two European families. A Dutch kindred displays a large homozygous genomic deletion encompassing exons 1-5 of the DJ-1 gene, whereas an Italian kindred harbors a single homozygous L166P missense mutation. A homozygous M26I missense mutation was also recently reported in an Ashkenazi Jewish patient with early onset PD. Mutations in DJ-1 are predicted to be loss of function. The recent determination of the crystal structure of human DJ-1 demonstrates that it exists in a homo-dimeric form in vitro, whereas the L166P mutant exists only as a monomer. Here, we examine the in vivo effects of the pathogenic L166P and M26I mutations on the properties of DJ-1 in cell culture. We report that the L166P mutation confers markedly reduced protein stability to DJ-1, which results from enhanced degradation by the 20S/26S proteasome but not from a loss of mRNA expression. Furthermore, the L166P mutant protein exhibits an impaired ability to self-interact to form homo-oligomers. In contrast, the M26I mutation does not appear to adversely affect either protein stability, turnover by the proteasome, or the capacity of DJ-1 to form homo-oligomers. These properties of the L166P mutation may contribute to the loss of normal DJ-1 function and are likely to be the underlying cause of early onset PD in affected members of the Italian kindred.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Autoantigens
  • Blotting, Northern
  • Blotting, Western / methods
  • Cell Line, Tumor
  • Cycloheximide / pharmacology
  • Electrophoresis, Gel, Pulsed-Field / methods
  • Humans
  • In Vitro Techniques
  • Intracellular Signaling Peptides and Proteins
  • Leucine / genetics
  • Methionine / pharmacokinetics
  • Mutation, Missense*
  • Oncogene Proteins / genetics*
  • Oncogene Proteins / immunology
  • Parkinsonian Disorders / genetics*
  • Parkinsonian Disorders / metabolism
  • Phenylalanine / genetics
  • Precipitin Tests / methods
  • Protein Deglycase DJ-1
  • Protein Synthesis Inhibitors / pharmacology
  • Proteins / metabolism
  • Proto-Oncogene Proteins c-myc / metabolism
  • RNA, Messenger / metabolism
  • Ribonucleoproteins / metabolism
  • SS-B Antigen
  • Sulfur Isotopes / pharmacokinetics
  • Transfection / methods

Substances

  • Autoantigens
  • Intracellular Signaling Peptides and Proteins
  • Oncogene Proteins
  • Protein Synthesis Inhibitors
  • Proteins
  • Proto-Oncogene Proteins c-myc
  • RNA, Messenger
  • Ribonucleoproteins
  • Sulfur Isotopes
  • Phenylalanine
  • Cycloheximide
  • Methionine
  • PARK7 protein, human
  • Protein Deglycase DJ-1
  • Leucine